Synpromics

Edinburgh, United Kingdom Founded: 2010 • Age: 16 yrs Acquired By AskBio
Synthetic promoters are designed for specific gene regulation.
Request Access

About Synpromics

Synpromics is a company based in Edinburgh (United Kingdom) founded in 2010 was acquired by AskBio in August 2019.. Synpromics has raised $9.86 million across 3 funding rounds from investors including AskBio, Scottish Enterprise and Calculus Capital. The company has 46 employees as of December 31, 2021. Synpromics operates in a competitive market with competitors including Amyris, Syngenta, Avidity Biosciences, AskBio and Univercells, among others.

  • Headquarter Edinburgh, United Kingdom
  • Employees 46 as on 31 Dec, 2021
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Synpromics Ltd
  • Date of Incorporation 27 Aug, 2010
  • Jurisdiction MIDLOTHIAN, SCOTLAND
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
    $125.77 K (USD)
    -94
    as on Dec 31, 2020
  • Net Profit
    $-4.83 M (USD)
    -119
    as on Dec 31, 2020
  • EBITDA
  • Total Equity Funding
    $9.86 M (USD)

    in 3 rounds

  • Latest Funding Round
    $2.43 M (USD), Grant

    Jun 01, 2018

  • Investors
    AskBio

    & 2 more

  • Employee Count
    46

    as on Dec 31, 2021

  • Acquired by
    AskBio

    (Aug 13, 2019)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Synpromics

Synpromics has successfully raised a total of $9.86M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $2.43 million completed in June 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Grant — $2.4M
  • First Round

    (14 Aug 2015)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2018 Amount Grant - Synpromics Valuation

investors

Apr, 2017 Amount Series B - Synpromics Valuation

investors

Aug, 2015 Amount Series A - Synpromics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Synpromics

Synpromics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include AskBio, Scottish Enterprise and Calculus Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
UK venture capital investments are managed by Calculus Capital.
Founded Year Domain Location
Business development and leadership training programs are offered to companies.
Founded Year Domain Location
Gene and protein therapies are developed for treating various diseases.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Synpromics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Synpromics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Synpromics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Synpromics

Synpromics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Syngenta, Avidity Biosciences, AskBio and Univercells, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of renewable products for industrial solutions
domain founded_year HQ Location
Crop protection solutions and hybrid seeds are provided for farming.
domain founded_year HQ Location
Antibody-siRNA complexes are developed for cancer treatment.
domain founded_year HQ Location
Gene and protein therapies are developed for treating various diseases.
domain founded_year HQ Location
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
domain founded_year HQ Location
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Synpromics

Frequently Asked Questions about Synpromics

When was Synpromics founded?

Synpromics was founded in 2010 and raised its 1st funding round 5 years after it was founded.

Where is Synpromics located?

Synpromics is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.

Is Synpromics a funded company?

Synpromics is a funded company, having raised a total of $9.86M across 3 funding rounds to date. The company's 1st funding round was a Series A of $3.28M, raised on Aug 14, 2015.

How many employees does Synpromics have?

As of Dec 31, 2021, the latest employee count at Synpromics is 46.

What is the annual revenue of Synpromics?

Annual revenue of Synpromics is $125.77K as on Dec 31, 2020.

What does Synpromics do?

Synpromics was founded in 2010 in Edinburgh, United Kingdom, within the biotechnology sector. Synthetic promoters are developed to enable precise gene expression control. These are screened through a platform to build a library optimized for the CHO system. Applications include cell and gene therapy, biologics bioprocessing, industrial biotechnology, agricultural biotechnology, and cell-based assays. Operations focus on patentable designs for targeted regulatory solutions.

Who are the top competitors of Synpromics?

Synpromics's top competitors include Syngenta, Sutro Biopharma and Avidity Biosciences.

Who are Synpromics's investors?

Synpromics has 3 investors. Key investors include AskBio, Scottish Enterprise, and Calculus Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available